In this video from Thursday's Market Checkup, Motley Fool health -are analyst David Williamson discusses a number of pharmaceutical companies that have aggressively reshaped themselves recently to deal with the effects of a looming patent cliff. Now, it seems that Merck (NYSE:MRK) may be on the verge of making a similar move. It is rumored that the company's consumer unit may be up for sale, and with such brands as Dr. Scholl's, Claritin, and Coppertone under that umbrella, the news is understandably generating a lot of interest. The potential sale is expected to raise roughly $11 billion
In this segment, David discusses the details of the potential deal, as well as just how far that $11 billion would go in restocking Merck's pipeline. David then takes a look at that pipeline and discusses some of its underrated potential blockbuster candidates.
The secret to investing in biotech stocks
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
David Williamson owns shares of Merck, Novartis, and Procter & Gamble. The Motley Fool recommends Procter & Gamble. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.